Studies indicate that the effectiveness of Programmed Cell Death Ligand 1 (PD-1/PD-L1) blockade varies significantly among different lymphomas, underscoring the importance of the TME in therapeutic responses [23,26,27,28]. The gene discussed is CD274; the disease is lymphoma.